文献速递泌尿生殖与妇科肿瘤放疗放疗物理与技术

基于治疗前PSMA-PET/CT原发灶与淋巴结影像组学预测局限期前列腺腺癌无转移生存

Prediction of metastasis-free survival in patients with localized prostate adenocarcinoma using primary tumor and lymph node radiomics from pre-treatment PSMA-PET/CT scans.
PubMed 文献 · Radiother Oncol · 2025-09-06

本研究纳入134例接受雄激素剥夺治疗(ADT)和体外放疗的前列腺腺癌(PCa)患者,从治疗前PSMA PET/CT的原发肿瘤和淋巴结体积中提取影像组学特征,结合临床因素构建Cox模型预测无转移生存(MFS)。结果显示联合原发灶与淋巴结影像组学的模型1在时间事件分析和5年MFS二分类中均表现最佳,测试集C-index为0.69,AUC为0.81。

要点

  • 联合原发灶与淋巴结影像组学的模型1预测MFS性能最佳,测试集C-index 0.69。
  • 模型1的5年MFS二分类测试集敏感度76.3%、特异度82.5%、AUC 0.81。
  • 仅用临床变量的模型3测试集C-index仅0.54,加入影像组学可提升预后预测。

核心结论

  • 治疗前PSMA-PET/CT影像组学联合临床因素可预测局限期前列腺腺癌患者的无转移生存,整合淋巴结与原发肿瘤影像组学预后性能最佳。

研究设计与样本

  • 回顾性队列研究纳入134例接受ADT和体外放疗的前列腺腺癌患者,其中28例有淋巴结受累。
  • 从治疗前PSMA PET/CT的CT和PET图像分割原发肿瘤(GTVp)和淋巴结(GTVn)体积,并定义原发肿瘤外5 mm扩展环区域。
  • 对影像组学特征行Z-score归一化和主成分分析(PCA)降维,构建三个Cox回归模型:模型1(临床+原发灶+淋巴结影像组学)、模型2(临床+原发灶影像组学)、模型3(仅临床)。
  • 因MFS数据不平衡(转移24例,无转移110例),采用70:30训练-测试集划分并对训练数据做不平衡校正。

主要发现

  • 时间事件分析C-index:模型1训练集0.77 [0.72, 0.78]、测试集0.69 [0.64, 0.70];模型2训练集0.72 [0.66, 0.73]、测试集0.63 [0.58, 0.64];模型3训练集0.62 [0.57, 0.63]、测试集0.54 [0.51, 0.56]。
  • 5年MFS二分类分析[敏感度, 特异度, AUC]:模型1训练集[83.6%, 91.3%, 0.88]、测试集[76.3%, 82.5%, 0.81];模型2训练集[77.4%, 85.1%, 0.84]、测试集[71.5%, 78.2%, 0.76];模型3训练集[69.3%, 78.2%, 0.76]、测试集[64.7%, 72.6%, 0.68]。
  • 模型1分类的两组患者实际生存曲线差异有统计学意义,证明分类有效。

关键数值与推荐

  • 单变量Cox回归以logistic回归p < 0.05筛选预测因子。
  • 多变量Cox回归在 imbalance-corrected 训练数据上拟合,并在测试数据上验证(使用训练集选出的预测因子)。

临床怎么用

  • 治疗前PSMA-PET/CT影像组学可作为预后生物标志物,辅助临床医生为原发前列腺癌患者制定个体化治疗策略。

局限性

  • MFS数据不平衡(转移24例,无转移110例),需不平衡校正。
  • 样本量有限(134例),需外部验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To predict metastasis-free survival (MFS) for patients with prostate adenocarcinoma (PCa) treated with androgen deprivation therapy (ADT) and external radiotherapy using clinical factors and radiomics extracted from primary tumor and node volumes in pre-treatment PSMA PET/CT scans. MATERIALS/METHODS: Our cohort includes 134 PCa patients (nodal involvement in 28 patients). Gross tumor volumes of primary tumor (GTVp) and nodes (GTVn) on CT and PET scans were segmented. A 5 mm expansion ring area outside primary tumor was defined. Z-score normalization was applied to radiomics features extracted from tumor and ring; dimension reduction was performed using Principal Components Analysis (PCA). For patients with only primary tumor, we took 3 principal components (PCs) from GTVp and one ring PC as representative radiomics components from CT and PET scans. For patients with nodes, we calculated weighted average (by volume) of radiomics from primary tumor and nodes, computed first 3 PCs and combined it with 1st PC from the ring. Radiomics PCs and clinical variables (age, Gleason score, initial prostate specific antigen value (i PSA), PSA_relapse) formed the predictors. Due to MFS data imbalance (metastasis-24, no metastasis-110), we performed 70:30 train-test split and applied imbalance correction to training data. Univariate Cox-regression was used to select top predictors (logistic regression p < 0.05). Multivariate Cox-regression was performed on imbalance-corrected training data and fit on testing data (using predictors selected from training). Model 2 was built using clinical variables and radiomic PCs from primary tumors (GTVp, ring). Model 3 was built using clinical variables only. Binary classification analysis for prediction of five-year MFS was also performed. RESULTS: Results of time-to-event analysis (MFS) were: Cox-regression c-scores: model1: train- 0.77 [0.72, 0.78]; test- 0.69 [0.64, 0.70]; model2: train- 0.72 [0.66, 0.73]; test- 0.63 [0.58, 0.64]; model3: train- 0.62 [0.57, 0.63]; test- 0.54 [0.51, 0.56]. The results of 5 year MFS classification analysis were [sensitivity, specificity, AUC]: model 1: train- [83.6 %, 91.3 %, 0.88]; test- [76.3 %, 82.5 %, 0.81]; model 2: train- [77.4 %, 85.1 %, 0.84]; test- [71.5 %, 78.2 %, 0.76]; model 3: train- [69.3 %, 78.2 %, 0.76]; test- [64.7 %, 72.6 %, 0.68]. The two cohorts of patients classified by model 1 showed statistically significant differences in their actual survival curves, demonstrating the efficacy of the classification. Integration of node with primary tumor-radiomics provides the best prognostic performance in MFS prediction. CONCLUSION: This is one of the first studies to explore the prognostic value of pre-treatment PSMA-PET, a relatively recent advancement in the care of prostate adenocarcinoma patients. Results demonstrated the potential of using imaging biomarkers from PSMA-PET/CT images for prognosis prediction before the treatment, which provides clinicians valuable information for customizing the treatment paradigm to improve the outcomes for primary prostate cancer patients.

来源:Radiother Oncol,查看原文。版权归原作者所有。

引用

  1. Singh A, Mendes WS, Oh SB, et al. Prediction of metastasis-free survival in patients with localized prostate adenocarcinoma using primary tumor and lymph node radiomics from pre-treatment PSMA-PET/CT scans. Radiother Oncol. 2025. PMID: 40921333. doi:10.1016/j.radonc.2025.111119

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。